Demonstrating the Clinical Utility of Next Generation Sequencing in Oncology

June 10, 2020
11 am to 12 pm EDT

Sponsored by

Webinar Description:
Next Generation Sequencing (NGS) is changing the way cancer patients are managed, offering a comprehensive view of a patient’s genetic profile. With the ability to detect variants across large numbers of genes in a single analysis, NGS can replace an iterative testing paradigm of single gene or small multi-gene panels, potentially shortening the time to diagnosis and intervention with a targeted therapy.  But while the promise of NGS in clinical practice is enormous, widespread adoption of the technology has been hampered by several factors, chief among them  inconsistent payer coverage and reimbursement for testing. Developing more robust evidence of the clinical utility of comprehensive NGS panels is a key step in securing coverage, routinizing reimbursement, and thus expanding clinical adoption of NGS in the clinic. 

The webinar will explore the current clinical and lab adoption landscape for NGS in oncology.  The reimbursement and funding context will also be reviewed for several global markets.  An overview of the key value propositions of comprehensive genomic profiling (CGP) will be highlighted, including an assessment of the growing body of evidence of clinical utility.  Finally, implications for innovators will be discussed, including clinical and non-clinical evidence investment, lab cost considerations, and key market scenarios that could become drivers or barriers to widespread clinical adoption and payer reimbursement for NGS in oncology.

Webinar attendees will build an understanding of the following key issues:

  • Value proposition of NGS and comprehensive genomic profiling in oncology
  • Current clinical practice and guidelines environment
  • Lab adoption and practice dynamics for NGS
  • Coverage and reimbursement or funding landscape for NGS in the US, Europe, and Japan
  • Overview of types and range of evidence to support the value of NGS and CGP in oncology
  • Evidence gaps most often cited by payers
  • Implications for oncology innovators


Joseph-FerraraJoseph Ferrara, President & CEO, Boston Healthcare Associates
Joe has over 20 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and health care IT clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis, and business development strategy. He has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovation health care technologies. Joe writes and speaks extensively on the value of medical technology innovation, with particular focus on precision medicine, advanced diagnostics, and oncology informatics. Prior to his consulting role, Joe led a joint venture between Boston Healthcare and a non-profit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research. Joe completed undergraduate studies at the University of Cincinnati and received his master’s degree from Harvard University.

Shivang-DoshShivang Doshi, Executive Director, Boston Healthcare Associates
Shivang Doshi has worked with a variety of pharmaceutical and diagnostics clients on issues related to market access, evidence development and reimbursement strategies of novel diagnostic technologies. His specific areas of expertise include value-based molecular assays, companion diagnostics, and informatics tools that support the delivery of precision medicine. Mr. Doshi’s prior experiences include cancer drug discovery at Novartis Institutes for Biomedical Research and global health policy at the Dana Farber Cancer Institute. Mr. Doshi has a Master of Public Health from Harvard School of Public Health and a Master’s degree in Biotechnology from Johns Hopkins University.